Inomagen Therapeutics Receives Up to $2.9 Million NIH Grant for Atrial Fibrillation Gene Therapy
Inomagen Therapeutics, Inc. has been awarded a Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH), potentially worth up to $2.9 million. The funding will support preclinical and manufacturing work for its gene therapy candidate targeting atrial fibrillation.
Inomagen Therapeutics, Inc. announced on September 16, 2026, that it has received a grant from the National Institutes of Health (NIH) under its Small Business Innovation Research (SBIR) program. The grant could provide up to $2.9 million to advance the company's gene therapy for atrial fibrillation.
The funding is designated to support crucial preclinical studies and manufacturing processes. These activities are intended to move the disease-modifying gene therapy program closer to an Investigational New Drug (IND) application. Atrial fibrillation is a common heart condition characterized by irregular heartbeats, which can increase the risk of stroke and heart failure.
Inomagen is developing a non-viral gene therapy approach to treat atrial fibrillation. The specifics of the therapy involve delivering genetic material designed to correct or mitigate the underlying causes of the condition. The non-viral aspect suggests a potential advantage in terms of safety and manufacturing scalability compared to methods using viral vectors.
The NIH SBIR program supports small businesses engaged in scientific research and development with the potential for commercialization. This award underscores the agency's interest in novel therapeutic strategies for cardiovascular diseases. Inomagen plans to leverage this grant to gather essential data required for regulatory submissions and further clinical development.